The OncLive Non-Hodgkin Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on various types of non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in non-Hodgkin lymphoma.
FDA Approval Sought for Parsaclisib in 3 Types of Relapsed/Refractory Non-Hodgkin LymphomaNovember 1st 2021
The FDA has accepted a new drug application for the PI3Kδ inhibitor parsaclisib for use in the treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma.
CAR T-cell Therapy CTX110 Shows Early Promise for Relapsed/Refractory CD19+ B-cell MalignanciesOctober 13th 2021
The allogeneic CD19-targeted CAR T-cell therapy CTX110 was found to elicit encouraging responses with favorable tolerability in patients with relapsed or refractory B-cell malignancies, according to data from the phase 1 CARBON trial.
Epcoritamab Shows Robust Antitumor Activity, Acceptable Safety in Relapsed/Refractory B-cell Non-Hodgkin LymphomaSeptember 30th 2021
Epcoritamab had a manageable toxicity profile when subcutaneously administered to patients with relapsed/refractory B-cell non-Hodgkin lymphoma and was found to elicit encouraging responses in those who were heavily pretreated.
Zanubrutinib Approaches EU Approval for Waldenström MacroglobulinemiaSeptember 17th 2021
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion regarding the use of zanubrutinib in adult patients with Waldenström macroglobulinemia who have previously received at least 1 therapy or in the frontline treatment of patients who are not eligible for chemoimmunotherapy.
FDA Approves Zanubrutinib for Relapsed or Refractory Marginal Zone LymphomaSeptember 15th 2021
The FDA has granted an accelerated approval to zanubrutinib for the treatment of adult patients with relapsed or refractory marginal zone lymphoma who have received at least 1 anti–CD20-based regimen.
CAR T-Cell Therapies Show Promise Across Indolent LymphomasSeptember 10th 2021
CAR T-cell products targeting CD19 are eliciting clinical activity in patients with indolent non-Hodgkin lymphoma, as seen in the ZUMA-5, SCHOLAR-5, and ELARA trials, but longer follow-up will showcase the true potential of this treatment in this subpopulation.
Tafasitamab Plus Lenalidomide Approved in Europe for Relapsed/Refractory DLBCLAugust 27th 2021
The European Commission has granted a conditional marketing authorization to tafasitamab plus lenalidomide followed by single-agent tafasitamab for use in adult patients with relapsed/refractory diffuse large B-cell lymphoma who are not candidates for autologous stem cell transplant.
Next Steps With Loncastuximab Tesirine in LBCL Involve Exploring Novel Combo Regimens
Paolo F. Caimi, MD, discusses the FDA approval of loncastuximab tesirine in large B-cell lymphoma, results from the phase 2 LOTIS-2 trial, and future research directions with the agent.
Off-the-Shelf NK Cell Products FT596 and FT516 Show Early Promise in B-cell LymphomaAugust 23rd 2021
Regimens that included the off-the-shelf, induced pluripotent stem cell–derived natural killer cell products FT596 and FT516 were found to elicit encouraging responses with favorable tolerability when used in patients with B-cell lymphoma.
Future of Care for PCNSL Relies on Adapting Personalized ApproachesAugust 23rd 2021
Primary central nervous system lymphoma is a rare and aggressive variant of extranodal non-Hodgkin lymphoma that occurs in the brain, spinal cord, cerebrospinal fluid, or eyes in the absence of systemic disease.
Mosunetuzumab Elicits Durable Response in Elderly Patients With DLBCLAugust 20th 2021
Updated outcomes from the ongoing phase 1/2 GO40554 trial show that mosunetuzumab monotherapy demonstrated promising efficacy and a tolerable safety for elderly/unfit patients with previously untreated first-line diffuse large B-cell lymphoma.
Zandelisib/Zanubrutinib Produces Promising Safety, Efficacy in Relapsed/Refractory B-Cell Malignancies
Alexey V. Danilov, MD, discusses the safety and efficacy achieved with the novel combination comprised of zandelisib and zanubrutinib in patients with relapsed/refractory B-cell malignancies.
Zandelisib Plus Rituximab Under Study in Indolent Non-Hodgkin LymphomaAugust 13th 2021
Zandelisib plus rituximab is being evaluated as a potentially chemotherapy-free treatment strategy vs standard chemoimmunotherapy in patients with indolent non-Hodgkin lymphoma in first relapse in the ongoing, phase 3 COASTAL trial.
Zanubrutinib Shows Encouraging Tolerability, Activity in BTK Inhibitor–Intolerant B-Cell MalignanciesAugust 12th 2021
Zanubrutinib demonstrated clinical activity and tolerability in previously treated patients with B-cell malignancies who were intolerant to therapy with ibrutinib and/or acalabrutinib, according to results of the phase 2 BGB-3111-215 trial.
Polatuzumab Vedotin Plus R-CHP Significantly Improves PFS Over R-CHOP in DLBCLAugust 9th 2021
Polatuzumab vedotin-piiq in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone resulted in a statistically significant and clinically meaningful improvement in progression-free survival vs rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with diffuse large B-cell lymphoma.